Delivery Order SPE2DR25D1100-SPE2DR26FCQ5B
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,167.66 on November 10, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages). This is a firm fixed price, non-set-aside contract with performance through November 12, 2025, and fulfillment at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a $12,851.51 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Xifaxan 550 mg tablets (60-count). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The order is scheduled for completion by September 24, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $6,558.15. This is a firm fixed price delivery order with an ultimate completion date of June 20, 2025, and carries no set-aside designation, indicating it was awarded through competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $28,942.08. This firm fixed-price delivery order, which is expected to be completed by August 25, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract valued at $2,392.21. The order carries an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $11,688.02 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on November 13, 2025, with completion scheduled for November 14, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical delivery under the company's broader federal supply relationship. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a Delivery Order valued at $5,518.26 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 23, 2025, with completion scheduled for September 24, 2025. This firm fixed-price contract represents a non-competitive delivery order placed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $35,629.10 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a $2,053.56 delivery order to AmerisourceBergen Drug Corp for Xifaxan 550 mg tablets (60-count) on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $31,394.70 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on November 12, 2025, with an ultimate completion date of November 13, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCQ5BDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $2,603.49. This non-set-aside delivery order was awarded on November 20, 2025, with an ultimate completion date of November 21, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and distribution operations. This delivery order represents a small-value transaction executed under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications, vaccines, and medical supplies to military and veteran healthcare systems. The company's extensive portfolio of competitively awarded federal contracts demonstrates its established capability to meet Defense Logistics Agency medical procurement requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 11/20/25 |